| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Organon & Co. | Director | Phantom Stock | 36.5K | $756K | $20.75 | Jun 7, 2024 | Direct |
| Fulcrum Therapeutics, Inc. | Director | Stock Option (right to buy) | 30K | Jun 17, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | Jun 17, 2024 | 1 | $0 | 4 | Jun 18, 2024 | Director |
| OGN | Organon & Co. | Jun 7, 2024 | 1 | $200K | 4 | Jun 11, 2024 | Director |
| FULC | Fulcrum Therapeutics, Inc. | Jun 27, 2023 | 1 | $0 | 4 | Jun 29, 2023 | Director |
| OGN | Organon & Co. | Jun 9, 2023 | 1 | $200K | 4 | Jun 13, 2023 | Director |
| FULC | Fulcrum Therapeutics, Inc. | Jun 27, 2022 | 2 | $0 | 4 | Jun 29, 2022 | Director |
| OGN | Organon & Co. | Jun 10, 2022 | 1 | $200K | 4 | Jun 14, 2022 | Director |
| FULC | Fulcrum Therapeutics, Inc. | Jun 9, 2021 | 1 | $0 | 4 | Jun 11, 2021 | Director |
| OGN | Organon & Co. | Jun 4, 2021 | 1 | $316K | 4 | Jun 8, 2021 | Director |
| OGN | Organon & Co. | Jun 2, 2021 | 0 | $0 | 3 | Jun 2, 2021 | Director |